
TY  - JOUR
TI  - Local Speakers
JO  - Asia-Pacific Journal of Clinical Oncology
JA  - Asia‐Pac J Clin Oncol
VL  - 10
IS  - S8
SN  - 1743-7555
UR  - https://doi.org/10.1111/ajco.12315
DO  - doi:10.1111/ajco.12315
SP  - 16
EP  - 36
PY  - 2014
ER  - 

TY  - JOUR
TI  - Posters
JO  - Diabetic Medicine
VL  - 23
IS  - s4
SN  - 0742-3071
UR  - https://doi.org/10.1111/j.1464-5491.2006.02036_12.x
DO  - doi:10.1111/j.1464-5491.2006.02036_12.x
SP  - 57
EP  - 199
PY  - 2006
ER  - 

TY  - JOUR
AU  - Denysenko, Tetyana
AU  - Gennero, Luisa
AU  - Juenemann, Carola
AU  - Morra, Isabella
AU  - Masperi, Paolo
AU  - Ceroni, Vincenzo
AU  - Pragliola, Antonella
AU  - Ponzetto, Antonio
AU  - Melcarne, Antonio
TI  - Heterogeneous phenotype of human glioblastoma: In vitro study
JO  - Cell Biochemistry and Function
JA  - Cell Biochem Funct
VL  - 32
IS  - 2
SN  - 0263-6484
UR  - https://doi.org/10.1002/cbf.2988
DO  - doi:10.1002/cbf.2988
SP  - 164
EP  - 176
KW  - glioblastoma
KW  - cancer stem cells
KW  - CD133
KW  - hydroxyurea
KW  - glioblastoma subtypes
PY  - 2014
AB  - Glioblastomas (GBMs) are the most lethal primary brain tumours. Increasing evidence shows that brain tumours contain the population of stem cells, so-called cancer stem cells (CSCs). Stem cell marker CD133 was reported to identify CSC population in GBM. Further studies have indicated that CD133 negative cells exhibiting similar properties and are able to initiate the tumour, self-renew and undergo multilineage differentiation. GBM is a highly heterogeneous tumour and may contain different stem cell populations with different functional properties. We characterized five GBM cell lines, established from surgical samples, according to the marker expression, proliferation and differentiation potential. CD133 positive cell lines showed increased proliferation rate in neurosphere condition and marked differentiation potential towards neuronal lineages. Whereas two cell lines low-expressing CD133 marker showed mesenchymal properties in vitro, that is high proliferation rate in serum condition and differentiation in mesenchymal cell types. Further, we compared therapy resistance capacity of GBM cell lines treated with hydroxyurea. Our results suggest that CSC concept is more complex than it was believed before, and CD133 could not define entire stem cell population within GBM. At least two different subtypes of GBM CSCs exist, which may have different biological characteristics and imply different therapeutic strategies. Copyright ? 2013 John Wiley & Sons, Ltd.
ER  - 

TY  - JOUR
TI  - Abstract Journal HPB Surgery
JO  - ANZ Journal of Surgery
JA  - ANZ Journal of Surgery
VL  - 89
IS  - S1
SN  - 1445-1433
UR  - https://doi.org/10.1111/ans.15189
DO  - doi:10.1111/ans.15189
SP  - 93
EP  - 104
PY  - 2019
ER  - 

TY  - JOUR
TI  - Poster Presentations
JO  - Australasian Journal of Dermatology
JA  - Australas J Dermatol
VL  - 59
IS  - S1
SN  - 0004-8380
UR  - https://doi.org/10.1111/ajd.17_12815
DO  - doi:10.1111/ajd.17_12815
SP  - 32
EP  - 129
PY  - 2018
ER  - 

TY  - JOUR
TI  - Abstracts presented at the 52nd Annual Meeting of the American Society of Dermatopathology
JO  - Journal of Cutaneous Pathology
JA  - J Cutan Pathol
VL  - 43
IS  - 1
SN  - 0303-6987
UR  - https://doi.org/10.1111/cup.12663
DO  - doi:10.1111/cup.12663
SP  - e1
EP  - e139
PY  - 2016
ER  - 

TY  - JOUR
TI  - 2012 Annual Meeting Sunday, October 7, 2012 Poster Session Abstracts
JO  - Annals of Neurology
JA  - Ann Neurol.
VL  - 72
IS  - S16
SN  - 0364-5134
UR  - https://doi.org/10.1002/ana.23769
DO  - doi:10.1002/ana.23769
SP  - S1
EP  - S120
PY  - 2012
ER  - 

TY  - JOUR
C8  - TME-2019-0033.R1
TI  - Abstracts-Speaker Sessions
JO  - Transfusion Medicine
JA  - Transfusion Med
VL  - 29
IS  - S2
SN  - 0958-7578
UR  - https://doi.org/10.1111/tme.12635
DO  - doi:10.1111/tme.12635
SP  - 3
EP  - 24
PY  - 2019
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - British Journal of Haematology
JA  - Br J Haematol
VL  - 176
IS  - S1
SN  - 0007-1048
UR  - https://doi.org/10.1111/bjh.14613
DO  - doi:10.1111/bjh.14613
SP  - 5
EP  - 145
PY  - 2017
ER  - 

TY  - JOUR
TI  - Proceedings of the Thrombosis and Hemostasis summit of North America: Research abstracts
JO  - American Journal of Hematology
JA  - Am. J. Hematol.
VL  - 87
IS  - S1
SN  - 0361-8609
UR  - https://doi.org/10.1002/ajh.23168
DO  - doi:10.1002/ajh.23168
SP  - S146
EP  - S200
PY  - 2012
ER  - 

TY  - JOUR
AU  - Asboe, D
AU  - Aitken, C
AU  - Boffito, M
AU  - Booth, C
AU  - Cane, P
AU  - Fakoya, A
AU  - Geretti, AM
AU  - Kelleher, P
AU  - Mackie, N
AU  - Muir, D
AU  - Murphy, G
AU  - Orkin, C
AU  - Post, F
AU  - Rooney, G
AU  - Sabin, C
AU  - Sherr, L
AU  - Smit, E
AU  - Tong, W
AU  - Ustianowski, A
AU  - Valappil, M
AU  - Walsh, J
AU  - Williams, M
AU  - Yirrell, D
AU  - BHIVA Guidelines Subcommittee
TI  - British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011
JO  - HIV Medicine
JA  - HIV Med
VL  - 13
IS  - 1
SN  - 1464-2662
UR  - https://doi.org/10.1111/j.1468-1293.2011.00971.x
DO  - doi:10.1111/j.1468-1293.2011.00971.x
SP  - 1
EP  - 44
KW  - antiretroviral-experienced
KW  - antiretroviral-naïve
KW  - assessment
KW  - HIV positive
KW  - monitoring
PY  - 2012
AB  - Table of Contents 1.?Levels of evidence 1.1?Reference 2.?Introduction 3.?Auditable targets 4.?Table summaries 4.1?Initial diagnosis 4.2?Assessment of ART-naïve individuals 4.3?ART initiation 4.4?Initial assessment following commencement of ART 4.5?Routine monitoring on ART 4.6?References 5.?Newly diagnosed and transferring HIV-positive individuals 5.1?Initial HIV-1 diagnosis 5.2?Tests to determine whether acquisition of HIV infection is recent 5.3?Individuals transferring care from a different HIV healthcare setting 5.4?Communication with general practitioners and shared care 5.5?Recommendations 5.6?References 6.?Patient history 6.1?Initial HIV-1 diagnosis 6.2?Monitoring of ART-naïve patients 6.3?Pre-ART initiation assessment 6.4?Monitoring individuals established on ART 6.5?Assessment of adherence 6.6?Recommendations 6.7?References 7.?Examination 7.1?Recommendations 8.?Identifying the need for psychological support 8.1?References 9.?Assessment of immune status 9.1?CD4 T cell counts 9.2?CD4 T cell percentage 9.3?References 10.?HIV viral load 10.1?Initial diagnosis/ART naïve 10.2?Post ART initiation 10.3?Individuals established on ART 10.4?Recommendations 10.5?References 11.?Technical aspects of viral load testing 11.1?References 12.?Viral load kinetics during ART and viral load ?blips? 12.1?References 13.?Proviral DNA load 13.1?References 14.?Resistance testing 14.1?Initial HIV-1 diagnosis 14.2?ART-naïve 14.3?Post treatment initiation 14.4?ART-experienced 14.5?References 15.?Subtype determination 15.1?Disease progression 15.2?Transmission 15.3?Performance of molecular diagnostic assays 15.4?Response to therapy 15.5?Development of drug resistance 15.6?References 16.?Other tests to guide use of specific antiretroviral agents 16.1?Tropism testing 16.2?HLA B*5701 testing 16.3?References 17.?Therapeutic drug monitoring 17.1?Recommendations 17.2?References 18.?Biochemistry testing 18.1?Introduction 18.2?Liver function 18.3?Renal function 18.4?Dyslipidaemia in HIV-infected individuals 18.5?Other biomarkers 18.6?Bone disease in HIV-infected patients 18.7?References 19.?Haematology 19.1?Haematological assessment and monitoring 19.2?Recommendations 19.3?References 20.?Serology 20.1?Overview 20.2?Hepatitis viruses 20.3?Herpes viruses 20.4?Measles and rubella 20.5?Cytomegalovirus (CMV) 20.6?References 21.?Other microbiological screening 21.1?Tuberculosis screening 21.2?Toxoplasma serology 21.3?Tropical screening 21.4?References 22.?Sexual health screening including anal and cervical cytology 22.1?Sexual history taking, counselling and sexually transmitted infection (STI) screening 22.2?Cervical and anal cytology 22.3?Recommendations 22.4?References 23.?Routine monitoring recommended for specific patient groups 23.1?Women 23.2?Older age 23.3?Injecting drug users 23.4?Individuals coinfected with HBV and HCV 23.5?Late presenters 23.6?References Appendix
ER  - 

TY  - JOUR
AU  - Malchesky, Paul S.
TI  - Artificial Organs 2017: A Year in Review
JO  - Artificial Organs
JA  - Artificial Organs
VL  - 42
IS  - 3
SN  - 0160-564X
UR  - https://doi.org/10.1111/aor.13137
DO  - doi:10.1111/aor.13137
SP  - 305
EP  - 331
KW  - Apheresis
KW  - —Artificial blood
KW  - —Bioengineering
KW  - —Blood pumps
KW  - —Cardiac support
KW  - —Cardiopulmonary
KW  - —Dermal
KW  - —Dialysis
KW  - —Functional electrical stimulation
KW  - —Medical devices
KW  - —Membrane oxygenation
KW  - —Organ preservation
KW  - —Orthopedic
KW  - —Pulmonary
KW  - —Renal
KW  - —Tissue engineering
KW  - —Transplantation
KW  - —Valves
KW  - —Vascular
KW  - —Vision
PY  - 2018
AB  - Abstract In this Editor's Review, articles published in 2017 are organized by category and summarized. We provide a brief reflection of the research and progress in artificial organs intended to advance and better human life while providing insight for continued application of these technologies and methods. Artificial Organs continues in the original mission of its founders ?to foster communications in the field of artificial organs on an international level.? Artificial Organs continues to publish developments and clinical applications of artificial organ technologies in this broad and expanding field of organ Replacement, Recovery, and Regeneration from all over the world. Peer-reviewed Special Issues this year included contributions from the 12th International Conference on Pediatric Mechanical Circulatory Support Systems and Pediatric Cardiopulmonary Perfusion edited by Dr. Akif Undar, Artificial Oxygen Carriers edited by Drs. Akira Kawaguchi and Jan Simoni, the 24th Congress of the International Society for Mechanical Circulatory Support edited by Dr. Toru Masuzawa, Challenges in the Field of Biomedical Devices: A Multidisciplinary Perspective edited by Dr. Vincenzo Piemonte and colleagues and Functional Electrical Stimulation edited by Dr. Winfried Mayr and colleagues. We take this time also to express our gratitude to our authors for offering their work to this journal. We offer our very special thanks to our reviewers who give so generously of time and expertise to review, critique, and especially provide meaningful suggestions to the author's work whether eventually accepted or rejected. Without these excellent and dedicated reviewers the quality expected from such a journal could not be possible. We also express our special thanks to our Publisher, John Wiley & Sons for their expert attention and support in the production and marketing of Artificial Organs. We look forward to reporting further advances in the coming years.
ER  - 

TY  - JOUR
TI  - ABSTRACTS—SYMPOSIA
JO  - Alcoholism: Clinical and Experimental Research
VL  - 32
IS  - s1
SN  - 0145-6008
UR  - https://doi.org/10.1111/j.1530-0277.2008.00684.x-i1
DO  - doi:10.1111/j.1530-0277.2008.00684.x-i1
SP  - 273A
EP  - 345A
PY  - 2008
ER  - 

TY  - JOUR
TI  - Abstracts of the 29th Annual Symposium of The Protein Society
JO  - Protein Science
JA  - Protein Science
VL  - 24
IS  - S1
SN  - 0961-8368
UR  - https://doi.org/10.1002/pro.2823
DO  - doi:10.1002/pro.2823
SP  - 1
EP  - 313
PY  - 2015
ER  - 

TY  - JOUR
TI  - Poster Session 1, Sunday 13 September
JO  - European Journal of Neurology
VL  - 16
IS  - s3
SN  - 1351-5101
UR  - https://doi.org/10.1111/j.1468-1331.2009.02821.x
DO  - doi:10.1111/j.1468-1331.2009.02821.x
SP  - 55
EP  - 334
PY  - 2009
ER  - 

TY  - JOUR
TI  - Thursday, 28 July 2011
JO  - Journal of Thrombosis and Haemostasis
VL  - 9
IS  - s2
SN  - 1538-7933
UR  - https://doi.org/10.1111/j.1538-7836.2011.04380_4.x
DO  - doi:10.1111/j.1538-7836.2011.04380_4.x
SP  - 712
EP  - 959
PY  - 2011
ER  - 

TY  - JOUR
TI  - Poster Session C
JO  - Pediatric Transplantation
JA  - Pediatr Transplantation
VL  - 19
IS  - S1
SN  - 1397-3142
UR  - https://doi.org/10.1111/petr.12517
DO  - doi:10.1111/petr.12517
SP  - 135
EP  - 152
PY  - 2015
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - British Journal of Haematology
VL  - 157
IS  - s1
SN  - 0007-1048
UR  - https://doi.org/10.1111/j.1365-2141.2012.09071.x
DO  - doi:10.1111/j.1365-2141.2012.09071.x
SP  - 1
EP  - 88
PY  - 2012
ER  - 

TY  - JOUR
TI  - Oral abstracts
JO  - Journal of Diabetes Investigation
JA  - J Diabetes Investig
VL  - 9
IS  - S1
SN  - 2040-1116
UR  - https://doi.org/10.1111/jdi.12938
DO  - doi:10.1111/jdi.12938
SP  - 19
EP  - 46
PY  - 2018
ER  - 

TY  - JOUR
TI  - Poster Session 2, Monday 27 September
JO  - European Journal of Neurology
VL  - 17
IS  - s3
SN  - 1351-5101
UR  - https://doi.org/10.1111/j.1468-1331.2010.03233.x
DO  - doi:10.1111/j.1468-1331.2010.03233.x
SP  - 351
EP  - 625
PY  - 2010
ER  - 
